While the recombinant yeast-brachyury vaccine is shown here to be more efficacious than the control yeast in the induction of brachyury-specific immune responses in vitro and in vivo and anti-tumor activity, the experiments reveal some degree of immune effect with control yeast. The gene discussed is TBX1; the disease is neoplasm.